Treatment of Acute Pneumonia

Overview

Step 1: Severity Assessment and Site-of-Care Decision

CURB-65 Score (Harrison's, 22nd ed.)

• C - Confusion (new onset)
• U - Urea >7 mmol/L (BUN >20 mg/dL)
• R - Respiratory rate ≥30/min
• B - Blood pressure: systolic ≤90 or diastolic ≤60 mmHg
• 65 - Age ≥65 years

Pneumonia Severity Index (PSI)

Mandatory ICU admission regardless of score:

• Septic shock requiring vasopressors
• Acute respiratory failure requiring mechanical ventilation
• Three or more minor ATS/IDSA criteria (RR ≥30, PaO₂/FiO₂ ≤250, multilobar infiltrates, confusion, BUN ≥20, leukopenia, thrombocytopenia, hypothermia, hypotension requiring fluids)

Step 2: Empiric Antibiotic Regimens (Community-Acquired Pneumonia)

Outpatient (No Comorbidities)

• Amoxicillin 1000 mg PO q8h for ≥5 days, OR
• Doxycycline 100 mg PO q12h for ≥5 days, OR
• Azithromycin 500 mg on day 1, then 250 mg qday days 2-5 (use only where local macrolide resistance <25%)

Outpatient (With Comorbidities: DM, heart/lung/liver/renal disease, malignancy, asplenia, alcoholism)

• Beta-lactam (amoxicillin-clavulanate 875/125 mg q12h, cefpodoxime 200 mg q12h, or cefuroxime 500 mg q12h) PLUS doxycycline or azithromycin, OR
• Respiratory fluoroquinolone monotherapy: levofloxacin 750 mg PO qday or moxifloxacin 400 mg PO qday

Inpatient (Non-Severe)

• Beta-lactam (ampicillin-sulbactam 1.5-3 g IV q6h, ceftriaxone 1-2 g IV qday, cefotaxime 1-2 g IV q8h, or ceftaroline 600 mg IV q12h) PLUS macrolide (e.g., azithromycin), OR
• Respiratory fluoroquinolone monotherapy (levofloxacin, moxifloxacin)

Inpatient (Severe CAP / ICU)

• Beta-lactam PLUS macrolide, OR
• Beta-lactam PLUS fluoroquinolone
• Do NOT use fluoroquinolone monotherapy for severe CAP

Step 3: Coverage for Resistant Organisms

MRSA Risk (prior respiratory isolation OR recent hospitalization + parenteral antibiotics in last 90 days)

• Non-severe disease: Obtain cultures and nasal PCR for MRSA; do not expand empirically unless confirmed
• Severe disease: Expand empirically with:
  • Vancomycin 15 mg/kg IV q12h (adjust by levels/renal function), OR
  • Linezolid 600 mg IV/PO q12h

Pseudomonas aeruginosa Risk (same risk factors as above)

• Expand empirically with an anti-pseudomonal agent:
  • Piperacillin-tazobactam 4.5 g IV q6h
  • Cefepime 2 g IV q8h, or ceftazidime 2 g IV q8h
  • Meropenem 1 g IV q8h, or imipenem 500 mg IV q6h
  • Aztreonam 2 g IV q8h (for penicillin allergy)

Step 4: Key Pharmacological Principles

Step 5: Supportive Care

Step 6: Hospital-Acquired Pneumonia (HAP) and VAP

• Non-severe, low MDR risk: Piperacillin-tazobactam OR cefepime OR ceftriaxone
• Severe or high MDR risk: Broaden to cover P. aeruginosa (two antipseudomonal agents) and MRSA (vancomycin or linezolid)
• Gram stain/culture of lower respiratory secretions should guide de-escalation
• VAP: treat at least 7-8 days; shorter courses (7 days) are favored when clinical response is adequate

Imaging: Typical Chest X-Ray Findings

Right upper lobe consolidation with well-defined inferior border along the horizontal fissure - classic lobar pneumonia

Community-acquired lobar pneumonia: (a) CXR consolidation, (b) lung ultrasound with air bronchograms

Key Points Summary

1. Assess severity first (CURB-65 or PSI) - this determines where and how aggressively to treat
2. Start antibiotics promptly - delays beyond 4 hours worsen outcomes
3. CAP outpatient: amoxicillin or doxycycline monotherapy for healthy patients; beta-lactam + macrolide or respiratory FQ for those with comorbidities
4. CAP inpatient non-severe: beta-lactam + macrolide or FQ monotherapy
5. Severe CAP/ICU: always dual therapy (beta-lactam + macrolide or FQ); never FQ monotherapy
6. Consider MRSA/Pseudomonas coverage if prior respiratory isolation or recent hospitalization with IV antibiotics
7. Duration: 5 days for responding non-severe CAP; 7 days for severe or slow responders
8. De-escalate once culture data available

Recent Evidence Note: The 2026 ATS Clinical Practice Guideline (PMID: 40679934) addresses four updated areas: lung ultrasound for diagnosis, whether to modify antibiotics when a respiratory virus test is positive, antibiotic duration, and corticosteroid use. It may refine some of the above thresholds - check the full guideline for the latest recommendations.

Related common dosing abbreviations:

Note: ODCM is commonly used in South Asian medical practice (India, etc.) as a local prescription shorthand. It is not a universally standardized abbreviation in Western pharmacopoeias, so always interpret it in the clinical context in which it appears.

Antibiotic of Choice for Tonsillitis

Causative Organism

First-Line Antibiotic

Penicillin V OR Amoxicillin - 10 days

"A 10-day course of penicillin or amoxicillin has traditionally been first-line treatment for acute GABHS infection in most cases." - Cummings Otolaryngology, Head and Neck Surgery

"First line: Penicillin OR Amoxicillin - 10 days" - Red Book 2021 (AAP), Treatment Table 4.12

Penicillin Allergy Alternatives

From Red Book 2021: "Allergy: Cephalexin OR Clindamycin OR Azithromycin"

Penicillin Failure (7-37% of cases)

• Amoxicillin-clavulanate (covers beta-lactamase-producing co-pathogens in the tonsil)
• Clindamycin
• Cephalosporins (cefuroxime, cephalexin)

1. Beta-lactamase protection by co-colonizing bacteria
2. Poor penicillin penetration into pharyngeal tissue
3. Loss of normal flora that inhibits GABHS virulence
4. Emerging macrolide resistance in GAS M-protein variants

Key Points

• Never use antibiotics for viral tonsillitis - most cases are viral; use Centor/McIsaac score or rapid antigen test to identify bacterial cases before prescribing
• Full 10-day course is essential to prevent rheumatic fever and glomerulonephritis (post-streptococcal sequelae)
• Do not use amoxicillin if EBV (mononucleosis) is suspected - it causes a widespread maculopapular rash in these patients
• Symptomatic relief: Paracetamol or NSAIDs; aspirin should be avoided (Reye syndrome risk in children)
• Steroids: Not routinely indicated; a single dose of dexamethasone may help symptom relief in severe cases per some guidelines, but is not standard practice
• Tonsillectomy is considered for truly recurrent strep tonsillitis: ≥7 episodes/year, ≥5/year for 2 years, or ≥3/year for 3 years - Cummings Otolaryngology, Table 201.4

Recent Evidence

Soothing Measures for Sore Throat / Tonsillitis

Pharmacological (Systemic)

Local / Topical Soothing

Home Remedies (Evidence-Supported)

What to Avoid

• Aspirin in children - risk of Reye syndrome
• Alcohol-based gargles - can irritate mucosa
• Dry, rough foods - worsen pain
• Smoking / secondhand smoke - delays healing

Quick Summary

1. Ibuprofen or paracetamol - most effective systemic relief
2. Benzydamine spray - best local topical option
3. Warm salt water gargle - simple, effective, safe
4. Cold fluids or ice cream - surprisingly effective local anaalgesia, especially in children post-tonsillectomy

IFA (Iron and Folic Acid) Tablets After Delivery - For the Mother

Short Answer

India's National Program (Anaemia Mukt Bharat / NHM)

Why IFA is Given Postpartum

1. Blood loss during delivery - average blood loss is 300-500 mL in normal vaginal delivery, more in caesarean - depletes iron stores significantly
2. Breastfeeding demands - lactation increases nutritional requirements
3. Prevention of postpartum anaemia - common cause of maternal morbidity and fatigue
4. Folic acid - supports tissue recovery and cellular regeneration after delivery
5. WHO recommendation - if a mother could not complete 6 months of IFA during pregnancy, she should continue supplementation postpartum to complete the full course

WHO Guideline

"If 6 months' duration cannot be achieved in pregnancy, continue to supplement during the postpartum period for 6 months, or increase the dose to 120 mg iron in pregnancy."

Key Points

• Yes, IFA is given postpartum - it is not stopped at delivery
• In India, it is given for 180 days post-delivery to lactating mothers
• The red-colored IFA tablet is used for pregnant and lactating women (distinguished from blue tablets for adolescents and pink tablets for children)
• ASHA workers are responsible for providing and counselling mothers about postpartum IFA supplementation at the community level
• Compliance is important - the tablets should be taken after food to reduce nausea/GI side effects